Opinion
Video
Author(s):
Panelists discuss key findings from the phase I/II study of the all-oral SAVE combination with revumenib in relapsed/refractory acute monocytic leukemia (R/R AML), the impact of the regimen's success in achieving high response and MRD negativity rates on integrating all-oral therapies into the treatment paradigm for R/R AML, particularly in patients with prior venetoclax or transplant exposure, and the potential role of revumenib in current treatment paradigms for R/R AML.
Video content above is prompted by the following: